Key regions: Germany, United States, India, Japan, United Kingdom
The demand for Anti-Rheumatic Drugs in Malawi has been increasing steadily over the past few years.
Customer preferences: Patients suffering from rheumatoid arthritis and other related diseases are the primary customers of Anti-Rheumatic Drugs in Malawi. These drugs are prescribed by rheumatologists and general practitioners, and are available in both branded and generic forms. Due to the high cost of branded drugs, many patients in Malawi prefer to use the generic versions.
Trends in the market: The Anti-Rheumatic Drugs market in Malawi has been growing at a steady pace due to the increasing prevalence of rheumatoid arthritis and related diseases. The market is dominated by non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying anti-rheumatic drugs (DMARDs). However, there has been a growing trend towards the use of biologic drugs, which are more expensive but have fewer side effects and are more effective in treating the disease.
Local special circumstances: Malawi has a high prevalence of rheumatoid arthritis and related diseases, which can be attributed to factors such as genetics, infections, and environmental factors. The lack of access to healthcare facilities and trained rheumatologists in rural areas has also contributed to the high prevalence of these diseases. Additionally, the high cost of branded drugs and the lack of insurance coverage for these drugs has led to the preference for generic drugs among patients.
Underlying macroeconomic factors: The Malawian economy has been growing at a slow pace over the past few years, with a GDP growth rate of around 3%. The healthcare sector in Malawi is underfunded and understaffed, with limited resources and infrastructure. The government has been taking steps to improve the healthcare sector, but progress has been slow. The lack of access to healthcare facilities and trained rheumatologists in rural areas has also contributed to the high prevalence of rheumatoid arthritis and related diseases. Additionally, the high cost of branded drugs and the lack of insurance coverage for these drugs has led to the preference for generic drugs among patients.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
